New advances in the hyperlipidemia treatment

dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorYoungRyun, Mo
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptKenézy Kórház, Központi Aneszteziológiai és Intezív Terápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2021-06-16T10:23:38Z
dc.date.available2021-06-16T10:23:38Z
dc.date.created2021-02-05
dc.description.abstractCurrent therapies of cardiovascular diseases have potency in reducing the risks. However, there are limitations and residual risks that remain. Non-adherence, drug resistance and side effects much often hinder the treatments that the optimal lipid level is often not reached in many patients. Recent advancement in medicine has allowed researchers to come up with a new strategy using antisense oligonucleotide and small-interfering RNA to target metabolic regulators present lipid metabolism which were once inaccessible and ‘undruggable’ by the conventional drugs.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent40hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/311139
dc.language.isoenhu_HU
dc.subjecthyperlipidemiahu_HU
dc.subjectnew treatments
dc.subject.dspaceNew advances in the hyperlipidemia treatmenthu_HU
dc.titleNew advances in the hyperlipidemia treatmenthu_HU
Fájlok